Matthew J Walter

List of Publications by Year
in descending order

116 papers	17,390 citations	71102 41 h-index	37204 96 g-index
121 all docs	121 docs citations	121 times ranked	24139 citing authors

#	Article	IF	Citations
1	Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia. Blood Cancer Discovery, 2022, 3, 32-49.	5.0	14
2	Failure to Detect Mutations in U2AF1 due to Changes in the GRCh38 Reference Sequence. Journal of Molecular Diagnostics, 2022, 24, 219-223.	2.8	13
3	Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells. Leukemia, 2022, 36, 935-945.	7.2	18
4	Toll-like receptor and cytokine expression throughout the bone marrow differs between patients with low- and high-risk myelodysplastic syndromes. Experimental Hematology, 2022, 110, 47-59.	0.4	7
5	Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression. Blood Cancer Discovery, 2022, 3, 330-345.	5.0	10
6	IL-1Î² expression in bone marrow dendritic cells is induced by TLR2 agonists and regulates HSC function. Blood, 2022, 140, 1607-1620.	1.4	4
7	Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. New England Journal of Medicine, 2021, 384, 924-935.	27.0	170
8	Nonsense-Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells Harboring SF3B1 or U2AF1 Mutations. Cancer Research, 2021, 81, 4499-4513.	0.9	28
9	Mutant U2AF1-induced alternative splicing of H2afy (macroH2A1) regulates B-lymphopoiesis in mice. Cell Reports, 2021, 36, 109626.	6.4	12
10	A synthetic small molecule stalls pre-mRNA splicing by promoting an early-stage U2AF2-RNA complex. Cell Chemical Biology, 2021, 28, 1145-1157.e6.	5.2	24
11	U2af1 is a haplo-essential gene required for hematopoietic cancer cell survival in mice. Journal of Clinical Investigation, 2021, 131, .	8.2	9
12	Adverse Outcomes in Acute Myeloid Leukemia Are Associated with Tumor Cell-Mediated Immunosuppression. Blood, 2021, 138, 800-800.	1.4	0
13	A Pilot Study of CPX-351 (Vyxeos Â©) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome. Blood, 2021, 138, 540-540.	1.4	8
14	Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study. Blood, 2021, 138, 1521-1521.	1.4	4
15	Haploinsufficiency of multiple del(5q) genes induce B cell abnormalities in mice. Leukemia Research, 2020, 96, 106428.	0.8	5
16	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	1.4	195
17	Genetics of progression from MDS to secondary leukemia. Blood, 2020, 136, 50-60.	1.4	80
18	Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS. Blood, 2020, 136, 32-33.	1.4	2

#	Article	IF	Citations
19	Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies. Blood, 2020, 136, 4-5.	1.4	2
20	Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML. Blood, 2020, 136, 2-3.	1.4	0
21	Mutant TRP53-R172H Has Gain-of-Function or Dominant-Negative Effects in Response to Different Hematopoietic Stressors in Mice. Blood, 2020, 136, 1-1.	1.4	0
22	U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nature Cell Biology, 2019, 21, 640-650.	10.3	165
23	Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. Haematologica, 2019, 104, e388-e392.	3.5	40
24	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	7.2	195
25	Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study. Blood, 2019, 134, 4271-4271.	1.4	0
26	Loss of Toll-like receptor 2 results in accelerated leukemogenesis in the NUP98-HOXD13 mouse model of MDS. Blood, 2018, 131, 1032-1035.	1.4	12
27	Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood, 2018, 131, 2402-2405.	1.4	30
28	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell Reports, 2018, 23, 270-281.e3.	6.4	177
29	Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nature Communications, 2018, 9, 455.	12.8	150
30	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. New England Journal of Medicine, 2018, 379, 2379-2380.	27.0	0
31	Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. New England Journal of Medicine, 2018, 379, 2330-2341.	27.0	322
32	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. New England Journal of Medicine, 2018, 379, 1028-1041.	27.0	93
33	Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS. Leukemia, 2018, 32, 1874-1878.	7.2	18
34	Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes. Cancer Research, 2018, 78, 5363-5374.	0.9	117
35	Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight, 2018, 3, .	5.0	48
36	Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study. Blood, 2018, 132, 4370-4370.	1.4	3

#	Article	IF	Citations
37	Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance. Blood, 2018, 132, 5277-5277.	1.4	0
38	Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nature Communications, 2017, 8, 14060.	12.8	99
39	CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell, 2017, 168, 801-816.e13.	28.9	177
40	Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. Blood, 2017, 129, 1397-1401.	1.4	24
41	Antecedent CHIP in CML?. Blood, 2017, 129, 3-4.	1.4	4
42	Splicing factor gene mutations in hematologic malignancies. Blood, 2017, 129, 1260-1269.	1.4	99
43	Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia, 2017, 31, 872-881.	7.2	87
44	Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells. PLoS ONE, 2017, 12, e0170470.	2.5	23
45	Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood, 2016, 127, 893-897.	1.4	94
46	Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome. Leukemia, 2016, 30, 2422-2426.	7.2	6
47	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 2016, 375, 2023-2036.	27.0	663
48	â€˜CHIPâ€™ping away at clonal hematopoiesis. Leukemia, 2016, 30, 1633-1635.	7.2	48
49	Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. Experimental Hematology, 2016, 44, 603-613.	0.4	44
50	Clinical Implications of Spliceosome Mutations: Epidemiology, Clonal Hematopoiesis, and Potential Therapeutic Strategies. Blood, 2016, 128, SCI-19-SCI-19.	1.4	3
51	The Role of H2AFY in U2AF1 Mutant Cells and Normal Hematopoiesis. Blood, 2016, 128, 963-963.	1.4	0
52	Rare Pre-Existing MDS Subclones Contribute to Secondary AML Progression. Blood, 2016, 128, 959-959.	1.4	12
53	DNMT3A-Dependent DNA Methylation May Act As a Tumor Suppressor-Not a Tumor Promoter-during AML Progression. Blood, 2016, 128, 1050-1050.	1.4	3
54	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood, 2015, 126, 2484-2490.	1.4	207

#	Article	IF	Citations
55	What came first: MDS or AML?. Blood, 2015, 125, 1357-1358.	1.4	5
56	Patterns and functional implications of rare germline variants across 12 cancer types. Nature Communications, 2015, 6, 10086.	12.8	243
57	U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing. Leukemia, 2015, 29, 909-917.	7.2	107
58	Reduced levels of Hspa9 attenuate Stat5 activation in mouse B cells. Experimental Hematology, 2015, 43, 319-330.e10.	0.4	15
59	Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing InÂVivo. Cancer Cell, 2015, 27, 631-643.	16.8	259
60	Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA - Journal of the American Medical Association, 2015, 314, 811.	7.4	302
61	Implications of Tumor Clonal Heterogeneity in the Era of Next-Generation Sequencing. Trends in Cancer, 2015, 1, 231-241.	7.4	25
62	Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature, 2015, 518, 552-555.	27.8	685
63	Preclinical Activity of Splicing Modulators in U2AF1 Mutant MDS/AML. Blood, 2015, 126, 1653-1653.	1.4	6
64	A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome. Blood, 2015, 126, 1686-1686.	1.4	1
65	Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy. Blood, 2015, 126, 610-610.	1.4	3
66	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. Blood, 2015, 126, 689-689.	1.4	1
67	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	1.4	85
68	Detection of Clonal Hematopoiesis in Cytopenic Patients Using Targeted Sequencing. Blood, 2015, 126, 1654-1654.	1.4	0
69	Characterization of Hematopoiesis in Tp53 R172H Mutant Mice. Blood, 2015, 126, 2452-2452.	1.4	2
70	Non-Malignant Oligoclonal Hematopoiesis Commonly Follows Cytoreductive Chemotherapy in Adult De Novo AML Patients. Blood, 2015, 126, 686-686.	1.4	0
71	SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution. PLoS Computational Biology, 2014, 10, e1003665.	3.2	400
72	Clonal Architecture of Secondary Acute Myeloid Leukemia Defined by Single-Cell Sequencing. PLoS Genetics, 2014, 10, e1004462.	3.5	115

#	Article	IF	Citations
73	Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 379-392.	16.8	330
74	Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Medicine, 2014, 20, 1472-1478.	30.7	1,533
75	The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia. Leukemia, 2014, 28, 1242-1251.	7.2	35
76	Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice. Blood, 2014, 124, 3887-3895.	1.4	20
77	TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. Blood, 2014, 124, 532-532.	1.4	6
78	Knockdown of HSPA9 Induces Apoptosis and Increases TP53 Levels in Human CD34+ Hematopoietic Progenitor Cells. Blood, 2014, 124, 526-526.	1.4	0
79	Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing in Transgenic Mice. Blood, 2014, 124, 827-827.	1.4	2
80	Mutational landscape and significance across 12 major cancer types. Nature, 2013, 502, 333-339.	27.8	3,695
81	Acquired copy number alterations of miRNA genes in acute myeloid leukemia are uncommon. Blood, 2013, 122, e44-e51.	1.4	13
82	Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia, 2013, 27, 1275-1282.	7.2	260
83	The Role Of Early TP53 Mutations On The Evolution Of Therapy-Related AML. Blood, 2013, 122, 5-5.	1.4	5
84	Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. Blood, 2013, 122, 2816-2816.	1.4	0
85	Reduced Hspa9 Expression Alters IL-7 Signaling In B-Cells. Blood, 2013, 122, 1569-1569.	1.4	0
86	Allele-Specific Effects Of U2AF1 Mutations On Alternative Splicing. Blood, 2013, 122, 2748-2748.	1.4	0
87	Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nature Genetics, 2012, 44, 53-57.	21.4	513
88	Clonal Architecture of Secondary Acute Myeloid Leukemia. New England Journal of Medicine, 2012, 366, 1090-1098.	27.0	688
89	Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 2012, 481, 506-510.	27.8	1,795
90	The Origin and Evolution of Mutations in Acute Myeloid Leukemia. Cell, 2012, 150, 264-278.	28.9	1,365

#	Article	IF	Citations
91	Mutant U2AF1(S34F) Expression Alters Hematopoiesis in Mice. Blood, 2012, 120, 553-553.	1.4	0
92	Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice. Blood, 2011, 117, 1530-1539.	1.4	72
93	Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia, 2011, 25, 1153-1158.	7.2	483
94	Identification of a Novel <emph type="ital">TP53</emph> Cancer Susceptibility Mutation Through Whole-Genome Sequencing of a Patient With Therapy-Related AML. JAMA - Journal of the American Medical Association, 2011, 305, 1568.	7.4	146
95	B-Cell Progenitors Are Reduced in Hspa9 haploinsufficient Mice,. Blood, 2011, 118, 3829-3829.	1.4	1
96	Dysfunctional DNA Double-Strand Break Repair Is Present in a Subset of Primary t-AML/t-MDS Myeloblasts. Blood, 2011, 118, 2415-2415.	1.4	0
97	DNA Sequence of the Cancer Genome of a Patient with Therapy-Related Acute Myeloid Leukemia. Blood, 2010, 116, 580-580.	1.4	0
98	Mutations In the DNA Methyltransferase Gene DNMT3A Are Highly Recurrent In Patients with Intermediate Risk Acute Myeloid Leukemia, and Predict Poor Outcomes. Blood, 2010, 116, 99-99.	1.4	9
99	Recurrent DNMT3A Mutations In Patients with Myelodysplastic Syndrome. Blood, 2010, 116, 608-608.	1.4	0
100	High-Resolution Comparative Genomic Hybridization of Mirna Genes In Therapy-Related AML Identifies a Somatic Deletion of MiR-223. Blood, 2010, 116, 2759-2759.	1.4	5
101	Detection of Novel Mutations In MDS/AML by Whole Genome Sequencing. Blood, 2010, 116, 299-299.	1.4	0
102	Dysfunctional Double-Strand DNA Break Repair In Primary t-AML/t-MDS Myeloblasts.. Blood, 2010, 116, 3366-3366.	1.4	0
103	Acquired copy number alterations in adult acute myeloid leukemia genomes. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12950-12955.	7.1	231
104	BRCA1 and BRCA2 Nucleotide Variants in Young Women with Therapy Related Acute Myeloid Leukemia.. Blood, 2009, 114, 1102-1102.	1.4	5
105	POU4F1 Is Associated with t(8;21) AML and Contributes Directly to Its Unique Transcriptional Signature.. Blood, 2009, 114, 2623-2623.	1.4	6
106	Del(5q): gene dosage matters. Blood, 2007, 110, 473-474.	1.4	4
107	Expression of a bcr-1 isoform of RARÎ±-PML does not affect the penetrance of acute promyelocytic leukemia or the acquisition of an interstitial deletion on mouse chromosome 2. Blood, 2007, 109, 1237-1240.	1.4	6
108	Comprehensive Genomic Copy Number and Sequence Analysis of 28 Chromosome 5q31.2 Candidate Genes in De Novo MDS.. Blood, 2007, 110, 117-117.	1.4	1

#	Article	IF	Citations
109	Reduced HSPA9B Expression, a 5q31.2 Candidate Gene, in Primary Human CD34+ Cells Recapitulates Features of Ineffective Hematopoiesis Observed in MDS.. Blood, 2007, 110, 116-116.	1.4	3
110	High Resolution Array-Based CGH and SNP Studies of AML Genomes.. Blood, 2007, 110, 107-107.	1.4	2
111	Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARÂ. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 12513-12518.	7.1	81
112	Detection of Microdeletions and Amplifications in Primary Human Acute Myeloid Leukemia (AML) Genomes Using Ultradense Oligomer Tiling Path Arrays and Comparative Genomic Hybridization (CGH).. Blood, 2005, 106, 2350-2350.	1.4	0
113	Genomic DNA Copy Number Alterations Present in AML Bone Marrow Samples with Normal Cytogenetics.. Blood, 2004, 104, 142-142.	1.4	4
114	Interleukin 12 P40 Production by Barrier Epithelial Cells during Airway Inflammation. Journal of Experimental Medicine, 2001, 193, 339-352.	8.5	152
115	Pancytopenia Secondary to Oxalosis in a 23-Year-Old Woman. Blood, 1998, 91, 4394-4394.	1.4	5
116	Targeted Inhibition of Interferon-Î³-dependent Intercellular Adhesion Molecule-1 (ICAM-1) Expression Using Dominant-Negative Stat1. Journal of Biological Chemistry, 1997, 272, 28582-28589.	3.4	90